| Literature DB >> 32318110 |
Kuma Diriba1, Tesfaye Kassa2, Yared Alemu3, Sisay Bekele4.
Abstract
BACKGROUND: Ocular disease with its complications is a major public health problem which has significant impacts on the quality of life particularly in developing countries. An eye infection due to bacterial agents can lead to reduced vision and blindness. This study was aimed to assess the antimicrobial susceptibility pattern and biofilm-forming potential of bacteria isolated from suspected external eye infected patients in Jimma.Entities:
Year: 2020 PMID: 32318110 PMCID: PMC7155758 DOI: 10.1155/2020/8472395
Source DB: PubMed Journal: Int J Microbiol
Prevalence of bacterial isolate against age groups at JUMC eye clinic.
| Name of bacterial isolate | Age in years | Total ( | ||||
|---|---|---|---|---|---|---|
| 0–2 ( | 3–16 ( | 17–30 ( | 31–45 ( | >45 ( | ||
| Gram-positive bacteria | ||||||
|
| 9 (20.5) | 2 (10.0) | 7 (31.8) | 2 (9.1) | 9 (23.1) |
|
| CoNS | 10 (22.7) | 5 (25.0) | 4 (18.2) | 11 (50.0) | 11 (28.2) |
|
|
| 4 (9.1) | 1 (5.0) | 2 (9.1) | 1 (4.5) | 5 (12.8) |
|
|
| 1 (2.3) | 3 (15.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) |
|
|
| 1 (2.3) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 3 (7.7) |
|
| S. viridians | 2 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.6) |
|
|
| ||||||
| Gram-negative bacteria | ||||||
|
| 1 (2.3) | 2 (10.0) | 2 (9.1) | 3 (13.6) | 2 (5.1) |
|
|
| 2 (4.5) | 2 (10.0) | 1 (4.5) | 1 (4.5) | 3 (7.7) |
|
|
| 1 (2.3) | 1 (5.0) | 2 (9.1) | 0 (0.0) | 1 (2.6) |
|
|
| 1 (2.3) | 1 (5.0) | 0 (0.0) | 1 (4.5) | 1 (2.6) |
|
|
| 2 (4.5) | 0 (0.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) |
|
|
| 2 (4.5) | 0 (0.0) | 0 (0.0) | 1 (4.5) | 2 (5.1) |
|
|
| 2 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.6) |
|
|
| 1 (2.3) | 1 (5.0) | 1 (4.5) | 2 (9.1) | 0 (0.0) |
|
|
| 4 (9.1)) | 0 (0.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) |
|
|
| 1 (2.3) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
| Total |
|
|
|
|
|
|
Coagulase-negative staphylococci.
Distribution of bacteria isolates against the different clinical features of external ocular infections at JUMC eye clinic.
| Name of bacterial isolate | Types of diagnosis | Total ( | ||||
|---|---|---|---|---|---|---|
| Conjunctivitis ( | Blepharitis ( | Blepharoconjunctivitis ( | Dacryocystitis ( | Others ( | ||
| Gram-positive bacteria | ||||||
|
| 15 (20.0) | 8 (25.0) | 1 (3.7) | 2 (25.0) | 3 (60) |
|
| CoNS | 16 (21.3) | 10 (31.2) | 10 (37.0) | 3 (37.5) | 2 (40) |
|
|
| 9 (12.0) | 2 (6.2) | 0 (0.0) | 2 (25.0) | 0 (0.0) |
|
|
| 4 (5.3) | 0 (0.0) | 1 (3.7) | 0 (0.0) | 0 (0.0) |
|
|
| 2 (2.7) | 2 (6.2) | 1 (3.7) | 0 (0.0) | 0 (0.0) |
|
|
| 2 (2.7) | 1 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
|
| ||||||
| Gram-negative bacteria | ||||||
|
| 5 (6.7) | 3 (9.4) | 2 (7.4) | 0 (0.0) | 0 (0.0) |
|
|
| 4 (5.3) | 2 (6.2) | 2 (7.4) | 1 (12.5) | 0 (0.0) |
|
|
| 3 (4.0) | 1 (3.1) | 1 (3.7) | 0 (0.0) | 0 (0.0) |
|
|
| 2 (2.7) | 0 (0.0) | 2 (7.4) | 0 (0.0) | 0 (0.0) |
|
|
| 3 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
|
| 3 (4.0) | 1 (3.1) | 1 (3.7) | 0 (0.0) | 0 (0.0) |
|
|
| 2 (2.7) | 0 (0.0) | 1 (3.7) | 0 (0.0) | 0 (0.0) |
|
|
| 2 (2.7) | 2 (6.2) | 1 (3.7) | 0 (0.0) | 0 (0.0) |
|
|
| 2 (2.7) | 0 (0.0) | 3 (11.1) | 0 (0.0) | 0 (0.0) |
|
|
| 1 (1.3) | 0 (0.0) | 1 (3.7) | 0 (0.0) | 0 (0.0) |
|
| Total |
|
|
|
|
|
|
Coagulase-negative staphylococcus; #Viridans streptococci.
Antimicrobial susceptibility patterns of Gram-positive isolates from external eye infection at JUMC ophthalmic clinic.
| Bacterial isolate | Antimicrobial agents tested | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Pattern | AMC no. (%) | AMP no. (%) | CIP no. (%) | AK no. (%) | C no. (%) | CLN no. (%) | TE no. (%) | SXT no. (%) | ERY no. (%) | CN no. (%) | FOX no. (%) | P no. (%) | |
|
| 29 | S | 22 (75.9) | 5 (17.2) | 26 (89.7) | 20 (68.9) | 16 (55.2) | 24 (82.8) | 7 (24.1) | 9 (31.0) | 5 (17.2) | 21 (72.4) | 25 (86.2) | 4 (13.8) |
| R | 7 (24.1) | 24 (82.8) | 3 (10.3) | 9 (31.0) | 13 (44.8) | 5 (17.2) | 22 (75.9) | 20 (69.0) | 24 (82.8) | 8 (27.6) | 4 (13.8) | 25 (86.2) | ||
|
| ||||||||||||||
| CoNS | 41 | S | 37 (90.2) | 7 (17.1) | 32 (78.0) | 30 (73.2) | 23 (56.1) | 33 (80.5) | 12 (29.3) | 13 (31.7) | 11 (26.8) | 32 (78.0) | 29 (70.7) | 7 (17.1) |
| R | 4 (9.8) | 34 (82.9) | 9 (22.0) | 11 (26.8) | 18 (43.9) | 8 (19.5) | 29 (70.7) | 28 (68.3) | 30 (73.2) | 9 (22.0) | 12 (29.3) | 34 (82.9) | ||
|
| ||||||||||||||
|
| 13 | S | 13 (100) | 5 (38.5) | 11 (84.6) | 10 (76.9) | 10 (76.9) | 8 (61.5) | 5 (38.5) | 4 (30.8) | 7 (53.8) | 10 (76.9) | NT | 4 (30.8) |
| R | 0 (0.0) | 8 (61.5) | 2 (15.4) | 3 (23.1) | 3 (23.1) | 5 (38.5) | 8 (61.5) | 9 (69.2) | 6 (46.2) | 3 (23.1) | NT | 9 (69.2) | ||
|
| ||||||||||||||
|
| 5 | S | 5 (100) | 2 (40.0) | 4 (80.0) | 4 (80.0) | 4 (80.0) | 4 (80.0) | 2 (40.0) | 2 (40.0) | 3 (60.0) | 4 (80.0) | NT | 3 (60.0) |
| R | 0 (0.0) | 3 (60.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 3 (60.0) | 3 (60.0) | 2 (40.0) | 1 (20.0) | NT | 2 (40.0) | ||
|
| ||||||||||||||
|
| 5 | S | 5 (100) | 2 (40.0) | 5 (100) | 4 (80.0) | 4 (80.0) | 5 (100) | 2 (40.0) | 3 (60.0) | 4 (80.0) | 4 (80.0) | NT | 3 (60.0) |
| R | 0 (0.0) | 3 (60.0) | 0 (0.0) | 1 (20.0) | 1 (20.0) | 0 (0.0) | 3 (60.0) | 2 (40.0) | 1 (20.0) | 1 (20.0) | NT | 2 (40.0) | ||
|
| ||||||||||||||
|
| 3 | S | 3 (100) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) | 3 (100) | 2 (66.7) | 1 (33.3) | 2 (66.7) | 3 (100) | NT | 1 (33.3) |
| R | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 2 (66.7) | 1 (33.3) | 0 (0.0) | NT | 2 (66.7) | ||
CoNS: coagulase-negative staphylococci; S: susceptible; R: resistance; AMC: amoxicillin-clavulanic acid; AMP: ampicillin; CIP: ciprofloxacin; AK: amikacin; C: chloramphenicol; CLN: clindamycin; TE: tetracycline; SXT: trimethoprim-sulphamethoxazole; ERY: erythromycin; CN: gentamicin; FOX: cefoxitin; P: penicillin G; no.: number; NT: not tested. #Viridans streptococci. A few Intermediate susceptible isolates were included in the susceptible category.
Antimicrobial susceptibility patterns of Gram-negative isolates from an external eye infection at JUMC ophthalmic clinic.
| Bacterial isolate | Antimicrobial agents tested | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Pattern | AMC no. (%) | AMP no. (%) | CIP no. (%) | CRO no. (%) | C no. (%) | CAZ no. (%) | TE no. (%) | SXT no. (%) | CN no. (%) | TOB no. (%) | AK no. (%) | |
|
| 10 | S | 8 (80.0) | 5 (50.0) | 9 (90.0) | 8 (80.0) | 5 (50.0) | 1 (10.0) | 2 (20.0) | 3 (30.0) | 8 (80.0) | 3 (30.0) | 8 (80.0) |
| R | 2 (20.0) | 5 (50.0) | 1 (10.0) | 2 (20.0) | 5 (50.0) | 9 (90.0) | 8 (80.0) | 7 (70.0) | 2 (20.0) | 7 (70.0) | 2 (20.0) | ||
|
| |||||||||||||
|
| 9 | S | 8 (88.9) | 6 (66.7) | 9 (100) | 9 (100) | 8 (88.9) | 6 (66.7) | 4 (44.4) | 4 (44.4) | 8 (88.9) | 4 (44.4) | 8 (88.9) |
| R | 1 (11.1) | 3 (33.3) | 0 (0.0) | 0 (0.0) | 1 (11.1) | 3 (33.3) | 5 (55.6) | 5 (55.6) | 1 (11.1) | 5 (55.6) | 1 (11.1) | ||
|
| |||||||||||||
|
| 5 | S | 5 (100) | 4 (80.0) | 5 (100) | 4 (80.0) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 3 (60.0) | 5 (100) | 2 (40.0) | 5 (100) |
| R | 0 (0.0) | 1 (20.0) | 0 (0.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 2 (40.0) | 0 (0.0) | 3 (60.0) | 0 (0.0) | ||
|
| |||||||||||||
|
| 4 | S | 4 (100) | 3 (75.0) | 4 (100) | 4 (100) | 4 (100) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 3 (75.5) | 1 (25.0) | 3 (75.0) |
| R | 0 (0.0) | 1 (25.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (25.0) | 1 (25.0) | 1 (25.0) | 1 (25.0) | 3 (75.0) | 1 (25.0) | ||
|
| |||||||||||||
|
| 3 | S | 3 (100) | 1 (66.7) | 3 (100) | 3 (100) | 3 (100) | 3 (100) | 2 (66.7) | 0 (0.0) | 3 (100) | 1 (33.3) | 2 (66.7) |
| R | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 3 (100) | 0 (0.0) | 2 (66.7) | 1 (33.3) | ||
|
| |||||||||||||
|
| 5 | S | 4 (80.0) | 4 (80.0) | 5 (100) | 5 (100) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 5 (100) | 4 (80.0) | 3 (60.0) | 4 (80.0) |
| R | 1 (20.0) | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 0 (0.0) | 1 (20.0) | 2 (40.0) | 1 (20.0) | ||
|
| |||||||||||||
|
| 3 | S | 3 (100) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) | 3 (100) | 1 (33.3) | 3 (100) | 2 (66.7) | 1 (33.3) | 2 (66.7) |
| R | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (66.7) | 0 (0.0) | 1 (33.3) | 2 (66.7) | 1 (33.3) | ||
|
| |||||||||||||
|
| 5 | S | 4 (80) | 3 (60.0) | 5 (100) | 5 (100) | 3 (60.0) | 4 (80.0) | 1 (20.0) | 4 (80.0) | 5 (100) | 2 (40.0) | 4 (80.0) |
| R | 1 (20.0) | 2 (40.0) | 0 (0.0) | 0 (0.0) | 2 (40.0) | 1 (20.0) | 4 (80.0) | 2 (40.0) | 0 (0.0) | 3 (60.0) | 1 (20.0) | ||
|
| |||||||||||||
|
| 5 | S | 4 (80.0) | 3 (60.0) | 5 (100) | 5 (100) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 3 (60.0) | 4 (80.0) | NT | NT |
| R | 1 (20.0) | 2 (40.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 2 (40.0) | 1 (20.0) | NT | NT | ||
|
| |||||||||||||
|
| 2 | S | NT | NT | 2 (100) | 2 (100) | 1 (50.0) | NT | NT | 1 (50.0) | NT | NT | NT |
| R | NT | NT | 0 (0.0) | 0 (0.0) | 1 (50.0) | NT | NT | 1 (50.0) | NT | NT | NT | ||
S: susceptible; R: resistance; AMC: amoxicillin-clavulanic acid; AMP: ampicillin; CIP: ciprofloxacin; AK: amikacin; C: chloramphenicol; TE : tetracycline; SXT: trimethoprim-sulphamethoxazole; CN: gentamicin; CRO: ceftriaxone; CAZ: ceftazidime; TOB: tobramycin; no.: number; NT: not tested. A few intermediate susceptible isolates were included in the susceptible category.
MDR pattern of bacteria isolated from external ocular infected patients at JUMC eye clinic.
| Bacterial isolates | Total | Antibiotic resistance pattern | |||||
|---|---|---|---|---|---|---|---|
| R0 | R1 | R2 | R3 | R4 | ≥R5 | ||
|
| 29 | 0 (0.0) | 0 (0.0) | 4 (13.8) | 5 (17.2) | 7 (24.1) | 13 (44.8) |
| CoNS | 41 | 0 (0.0) | 2 (4.9) | 5 (12.2) | 8 (19.5) | 10 (24.4) | 16 (39.0) |
|
| 13 | 0 (0.0) | 1 (7.7) | 3 (23.1) | 3 (23.1) | 6 (46.2) | 0 (0.0) |
|
| 5 | 0 (0.0) | 1 (20.0) | 0 (0.0) | 2 (40.0) | 1 (20.0) | 1 (20.0) |
|
| 5 | 1 (20.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 0 (0.0) | 1 (20.0) |
| S. viridians | 3 | 0 (0.0) | 2 (66.7) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) |
|
| 10 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (30.0) | 2 (20.0) | 5 (50.0) |
|
| 9 | 1 (11.1) | 1 (11.1) | 1 (11.1) | 4 (44.4) | 2 (22.2) | 0 (0.0) |
|
| 5 | 0 (0.0) | 2 (40.0) | 2 (40.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) |
|
| 4 | 0 (0.0) | 2 (50.0) | 1 (25.0) | 1 (25.0) | 0 (0.0) | 0 (0.0) |
|
| 3 | 0 (0.0) | 0 (0.0) | 2 (66.7) | 1 (33.3) | 0 (0.0) | 0 (0.0) |
|
| 5 | 1 (20.0) | 2 (40.0) | 0 (0.0) | 2 (40.0) | 0 (0.0) | 0 (0.0) |
|
| 3 | 0 (0.0) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 0 (0.0) |
|
| 5 | 0 (0.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) |
|
| 5 | 1 (20.0) | 2 (40.0) | 1 (20.0) | 1 (20.0) | 0 (0.0) | 0 (0.0) |
|
| 2 | 0 (0.0) | 2 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Total |
|
|
|
|
|
|
|
CoNS: coagulase-negative staphylococci; Ro: bacterial isolate susceptible to all antimicrobial agents tested; R1: bacterial isolate resistance to 1 antimicrobial agent; R2: bacterial isolate resistance to 2 antimicrobial agents of different classes; R3: bacterial isolate resistance to 3 antimicrobial agents of different classes; R4: bacterial isolate resistance to 4 antimicrobial agents of different classes; ≥R5: bacterial isolate resistance to 5 or more antimicrobial agents of different classes.
Figure 1Microtiter polystyrene (96-well) plate method used to categorize bacterial isolates as strong, moderate, weak, and nonbiofilm producers differentiated by crystal violet stain at JUMC.
Biofilm forming capability and adherence classification of bacteria from external ocular infected patients at JUMC ophthalmic clinic.
| Bacterial isolates | Biofilm formation classification | ||||
|---|---|---|---|---|---|
| Total | Strong | Moderate | Weak | Nonadherent | |
|
| 29 | 9 (31.0) | 10 (34.5) | 2 (6.9) | 8 (27.6) |
| CoNS | 41 | 14 (34.1) | 13 (31.7) | 4 (9.8) | 10 (24.4) |
|
| 5 | 0 (0.0) | 1 (20.0) | 1 (20.0) | 3 (60.0) |
|
| 5 | 0 (0.0) | 1 (20.0) | 1 (20.0) | 3 (60.0) |
| S. viridians | 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (100) |
|
| 10 | 4 (40.0) | 3 (30.0) | 1 (10.0) | 2 (20.0) |
|
| 9 | 2 (22.2) | 3 (33.3) | 2 (22.2) | 2 (22.2) |
|
| 5 | 1 (20.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) |
|
| 4 | 0 (0.0) | 0 (0.0) | 2 (50.0) | 2 (50.0) |
|
| 3 | 0 (0.0) | 1 (33.3) | 0 (0.0) | 2 (66.7) |
|
| 5 | 0 (0.0) | 3 (60.0) | 0 (0.0) | 2 (40.0) |
|
| 3 | 0 (0.0) | 1 (33.3) | 0 (0.0) | 2 (66.7) |
|
| 5 | 1 (20.0) | 2 (40.0) | 0 (0.0) | 2 (40.0) |
| Total |
|
|
|
|
|
S. pneumoniae (n = 13), H. influenzae (n = 5), and N. meningitidis (n = 2) altogether, their biofilm formation capability was not assessed for they are delicate and fastidious by nature.
Figure 2Relationship of antimicrobial resistance and biofilm formation of isolates from JUMC eye clinic.